Introduction
Estrogens have a significant role in the etiology and progression of breast cancers and mediate their actions through estrogen receptors (ERs), ER-a and ER-b, nuclear steroid receptors that regulate transcription either directly by binding to estrogen-response elements of target genes or indirectly through protein-protein interactions with other transcription factors (Kushner et al., 2000; Deroo and Korach, 2006) . Another factor known to have an important role in tumor progression is the vascular endothelial growth factor (VEGF) (Ferrara et al., 2003) . VEGF mediates its effects through its receptors, VEGFR1 and VEGFR2, and regulates angiogenesis in both physiological and pathological processes, including tumor-associated angiogenesis (Ferrara et al., 2003) . VEGF is highly expressed in many breast tumors and VEGF represents a major target for tumor therapy (Rugo, 2004; Ellis and Hicklin, 2008) .
Several studies have shown that estrogens modulate VEGF expression in breast and uterus tissues and in breast cancer cell lines (Hyder, 2006) . The VEGF gene is also known to be estrogen responsive and have ER-aregulatory components (Stoner et al., 2004; Kazi et al., 2005) . In addition, many tumors coexpress ER-a and VEGF (Kimbro and Simons, 2006) . VEGF expression is also induced by hypoxia (Ferrara et al., 2003; Kimbro and Simons, 2006) . The regulation of VEGF expression by hypoxia occurs because of the stabilization of hypoxia-inducible factor-1 alpha (HIF-1a) protein levels, which interacts with its constitutively expressed binding partner, HIF-1b, and the heterodimer binds the hypoxia-response element (HRE) in the VEGF promoter to induce its expression (Kimbro and Simons, 2006) . HIF-1a has been shown to be a positive regulator of tumor progression and high levels of HIF-1a expression occur in ER-a-positive and negative breast cancers (Bos et al., 2004; Kimbro and Simons, 2006; Liao et al., 2007) . In addition, estrogens have been shown to induce HIF-1a expression and enhance the recruitment of HIF1a to the VEGF promoter in the rat uterus and in endometrial cancer cells (Kazi et al., 2005; Molitoris et al., 2009) .
We have shown that increased expression of hexamethylene bisacetamide-inducible protein 1 (HEXIM1) inhibits breast cell growth (Wittmann et al., 2003) . We also demonstrated that HEXIM1 interacts with ER-a and decreases its transcriptional activity (Wittmann et al., 2005) . Several studies have also shown that HEXIM1 interacts with the positive transcription elongation factor b (P-TEFb) through cyclin T1 and inhibits its activity (Zhou and Yik, 2006) . P-TEFb is a complex of cyclin T1 and cyclin-dependent kinase 9 that phosphorylates the carboxy terminal domain of RNA polymerase II (RNAP II) to promote productive phases of transcription (Sims et al., 2004) . We found that estrogen enhances P-TEFb activity and increases the recruitment of P-TEFb to some ER-a target genes (Ogba et al., 2008) . HEXIM1 regulation of these genes involves inhibiting P-TEFb activity and recruitment to the ER-a target genes (Ogba et al., 2008) . In addition, a recent study from our laboratory uncovered a novel role of HEXIM1 as a regulator of VEGF during heart and vascular development using a mouse model with a C-terminus mutation in HEXIM1 .
Although it is known that estrogens can induce VEGF expression through ER-a in breast cancer cells, it is not known whether this regulation is dependent on P-TEFb. In addition, it is not known whether HEXIM1 regulates VEGF expression in breast cancer cells, the mammary gland and in mammary tumors. In this study, we demonstrate that in breast cells, HEXIM1 regulates VEGF expression by its effect on transcription factors ER-a and HIF-1a, suggesting an important role for HEXIM1 in mammary tumorigenesis.
Results
Increase in HEXIM1 expression inhibits estrogen-induced VEGF expression in breast cancer cells To determine the effect of HEXIM1 on VEGF expression, MCF-7 breast cancer cells, which are ERa-positive, were transfected with empty vector or pCMV-Tag2B-HEXIM1 and treated with ethanol (vehicle) or increasing concentrations of 17-b estradiol (E 2 ). There was a significant increase in VEGF mRNA expression in cells treated with 1 and 10 nM E 2 ( Figure 1a , lanes 2 and 3). Although the E 2 -induced increases in VEGF mRNA were modest (B1.5-fold increase relative to vehicle-treated cells), previous reports using breast cancer cells cultured in vitro have observed E 2 -induced increases in VEGF mRNA within a similar range (Maity et al., 2001; Higgins et al., 2006) . The MCF-7 cells were adequately responsive to E 2 , as there were significant increases in other ER target genes, including trefoil factor 1 (TFF1 or pS2) and progesterone receptor (Supplementary Figure 1) . Increased HEXIM1 expression in MCF-7 cells inhibited E 2 -induced increases in VEGF mRNA expression ( Figure 1a , lanes 5 and 6). Increased HEXIM1 expression also inhibited E 2 -induced pS2 mRNA expression but did not affect E 2 -induced progesterone receptor mRNA expression as previously reported (Supplementary Figure 1 ) (Ogba et al., 2008) .
From previous studies, we know that HEXIM1 inhibits E 2 /ER-a transcriptional activity in the context of some ER-a target genes (Wittmann et al., 2005; Ogba et al., 2008) . In ER-a-negative MDA-MB-231 cells, we found no change in VEGF mRNA expression in response to estrogen treatment or increased HEXIM1 expression (Figure 1b) , suggesting that the effect of increased HEXIM1 expression on VEGF mRNA expression requires E 2 /ER-a. To further test this hypothesis, we transfected MDA-MB-231 cells with control vector or pCMV-Tag2B-ER-a and treated cells with vehicle or E 2 . MDA-MB-231 cells are typically not E 2 responsive except in some cases of ER-a or ER-boverexpression (Buteau-Lozano et al., 2002) , but in our hands, we found that VEGF mRNA was slightly, but significantly responsive to E 2 in ER-a-expressing MDA-MB-231 cells (Supplementary Figure 2 , lane 3) and increased HEXIM1 expression inhibited the E 2 -induced increase in VEGF mRNA expression in these cells (Supplementary Figure 2 , lane 5).
To determine whether increased HEXIM1 expression exerted any effect on estrogen-induced secreted VEGF protein, we examined changes in the levels of secreted VEGF protein in the media of cultured MCF-7 cells and found that increased HEXIM1 expression decreased E 2 -induced secretion of VEGF protein from MCF-7 cells ( Figure 1c ). Taken together, these data suggest that HEXIM1 regulation of VEGF expression requires E 2 /ER-a.
Increased HEXIM1 expression inhibits the recruitment of E 2 /ER-a to the VEGF promoter Previous studies have determined that the VEGF promoter contains estrogen-responsive Sp1-binding sites and GC-rich motifs that contribute to E 2 /ER-a-driven VEGF transactivation (Stoner et al., 2004; Kazi et al., 2005) . To determine the effect of HEXIM1 on E 2 /ER-aregulated VEGF transcription, we carried out chromatin immunoprecipitation (ChIP) assays to examine changes in the recruitment of ER-a to a region in the VEGF promoter proximal to GC-rich/Sp1-binding elements. We found that increased HEXIM1 expression led to an increase in HEXIM1 occupancy at the VEGF promoter that did not seem to be E 2 dependent (Figure 1e ). This increased occupancy of HEXIM1 led to a decrease in the recruitment of E 2 /ER-a and RNAP II to the VEGF promoter (Figure 1e and Supplementary Figure 3a) . As a control, we examined the recruitment of ER-a to a region in the VEGF promoter that does not contain GC-rich/Sp1 sites (see control region in Figure 1d ) and did not observe any recruitment to this region (Supplementary Figure 3b) .
Previous studies from our laboratory have determined that HEXIM1 inhibits E 2 -driven transcription of some ER-a target genes in a P-TEFb-dependent manner (Wittmann et al., 2005; Ogba et al., 2008) . To determine whether P-TEFb is involved in E 2 /ER-adriven VEGF transcription, we immunoprecipitated cyclin T1 in the ChIP assays and found that cyclin T1 recruitment was not enhanced by E 2 treatment and increased HEXIM1 expression did not significantly affect its occupancy at the GC-rich/Sp1 region in the VEGF promoter (Figure 1e and Supplementary  Figure 3a) . We also examined the recruitment of cyclin T1 to the VEGF promoter control region HEXIM1 regulates VEGF function through ERa and HIF-1a N Ogba et al described earlier and found that cyclin T1 was also not recruited to this region (Supplementary Figure 3b) . Although it is possible that E 2 modulates cyclin T1 occupancy at other regions in the VEGF gene, these data suggest that P-TEFb recruitment to the GC-rich/Sp1 region of the VEGF promoter is not dependent on E 2 and not significantly affected by HEXIM1.
Under hypoxia, HEXIM1 inhibition of VEGF expression correlates with a decrease in E 2 -induced HIF-1a expression Low oxygen tension is another positive regulator of VEGF expression (Kimbro and Simons, 2006) . To determine the effect of HEXIM1 on hypoxia-induced VEGF expression in the presence or absence of E 2 , we transfected MCF-7 cells with control vector or 
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Flag-HEXIM1 expression vector and subjected the cells to either high oxygen (21% O 2 ) or low oxygen (1% O 2 ) conditions. We found that increased HEXIM1 expression inhibited E 2 -induced increases in VEGF mRNA expression under both 21 and 1% O 2 conditions ( Figure 2a ). However, under 1% O 2 conditions alone, HEXIM1 did not inhibit VEGF mRNA expression ( Figure 2a , compare lanes 5 and 7), suggesting that the effect of HEXIM1 on VEGF expression may involve the modulation of E 2 and hypoxia in concert. Studies have shown that both estrogens and hypoxia regulate VEGF expression in breast cancer cells (Maity et al., 2001; Seifeddine et al., 2007) . We found that E 2 and hypoxia (1% O 2 ) induced a slightly higher fold increase in VEGF mRNA expression when compared with E 2 under 21% O 2 conditions that is statistically significant (Po0.05) (Figure 2a ). However, there was no change in HIF-1a mRNA expression in response to E 2 treatment or increased HEXIM1 expression under 21 and 1% O 2 conditions (Figure 2a) , suggesting that the effect of HEXIM1 on HIF-1a is probably through post-translational regulation of HIF-1a. Western blot analyses showed that E 2 induced an increase in HIF-1a protein expression (Figure 2b ). However, increased HEXIM1 expression inhibited E 2 -induced increases in HIF-1a protein expression under hypoxia (Figure 2b , compare lanes 6 and 8). In MDA-MB-231 cells, we found that E 2 did not enhance HIF-1a protein expression and increased HEXIM1 expression did not affect HIF-1a protein expression (Figure 2c , see lanes 5-8). These data suggest that E 2 /ER-a regulates HIF-1a protein expression to enhance VEGF expression in breast cancer cells and that HEXIM1 modulates E 2 /ERa-regulated HIF-1a protein expression under low oxygen levels. 
HEXIM1 regulates VEGF function through ERa and HIF-1a
N Ogba et al HEXIM1 inhibits E 2 -induced HIF-1a recruitment to the HRE in the VEGF promoter Estrogens induce the recruitment of HIF-1a to the VEGF promoter in the rat uterus and in endometrial cancer cells (Kazi et al., 2005; Molitoris et al., 2009) . To verify that E 2 induces HIF-1a recruitment to the VEGF promoter in the context of breast epithelial cells in our studies, we carried out ChIP assays using MCF-7 cells that were treated with vehicle or E 2 and grown under 21% O 2 or hypoxic (0.5% O 2 ) conditions. We found that E 2 enhanced the recruitment of HIF-1a to HRE in the VEGF promoter under 0.5% O 2 (Figure 3a) . We also observed that some HIF-1a was immunoprecipitated under 21% O 2 conditions in MCF-7 cells (Figure 3a) , suggesting that HIF-1a binds to the VEGF HRE under these conditions and may have a role in regulating VEGF expression, but comparatively, under 0.5% O 2 we observed a significantly enhanced amount of HIF-1a present at the VEGF HRE. In MCF-7 cells treated with hypoxia mimetic, cobaltous chloride (CoCl 2 ) (Cho et al., 2005) , we observed a similar E 2 -induced increase in HIF-1a recruitment to the VEGF HRE (Figure 3a) . To determine the effect of HEXIM1 on E 2 -induced HIF-1a recruitment to the VEGF HRE in the presence or absence of ER-a, we carried out ChIP assays with MCF-7 and MDA-MB-231 cells. Under both 21 and 1% O 2 , E 2 induced the recruitment of HIF-1a to the VEGF HRE in MCF-7 cells and increased HEXIM1 expression resulted in a decrease in E 2 -induced recruitment of HIF-1a to the VEGF HRE (Figure 3b ) likely due to a decrease in HIF-1a protein expression under hypoxia (Figure 2b) . In MDA-MB-231 cells, hypoxia induced an increased HIF-1a recruitment to the VEGF HRE, but neither E 2 nor HEXIM1 significantly altered its occupancy on DNA (Figure 3c ). Taken together, these data suggest that HEXIM1 regulates VEGF transcription through both ER-a-and HIF-1a-dependent mechanisms. HEXIM1 regulates VEGF function through ERa and HIF-1a N Ogba et al HEXIM1 modulates VEGF and HIF-1a expression and angiogenesis in the mouse mammary gland independent of P-TEFb To determine whether increased HEXIM1 expression significantly alters E 2 -regulated VEGF and HIF-1a expression in the mammary gland, we extracted mammary glands from MMTV/HEXIM1 transgenic mice used in previous studies (Ogba et al., 2008) . These mice inducibly overexpress HEXIM1 in the mammary gland when treated with doxycycline ( þ DOX) and were ovariectomized and treated with E 2 to monitor changes in gene expression that are modulated by E 2 (Ogba et al., 2008) . We found that increased HEXIM1 expression ( þ DOX) significantly decreased VEGF and HIF-1a protein expression in the mammary gland (Figure 4a) .
To verify the physiological relevance of HEXIM1 regulation on VEGF in the mammary gland, we generated mice expressing a knock-in mutation of HEXIM1 that have been previously described . HEXIM1 is expressed at full length as a 359-amino acid protein, with the C-terminus containing inhibitory domains for ER-a and P-TEFb (Wittmann et al., 2005; Zhou and Yik, 2006) . These mice carry an insertional mutation in HEXIM1 that disrupts the C-terminus (HEXIM1 1À312 ). To demonstrate that the C-terminus mutation in HEXIM1 did not disrupt its potential to inhibit P-TEFb activity, we carried out in vitro kinase assays to compare the activity of wild-type HEXIM1 with HEXIM1 1À312 in Chinese hamster ovary cells. We found that HEXIM1 1À312 inhibits P-TEFb activity comparable to wild-type HEXIM1 (Supplementary Figure 4) . Previous studies showed that HEXIM1 1À312 interacts with P-TEFb . In vitro studies verified this and we also found that HEXIM1 1À312 interacts with Figure 4 HEXIM1 modulates VEGF and HIF-1a expression and vascularization in mouse mammary gland. (a) MMTV/HEXIM1 mice were treated as described in the Materials and methods, and mammary gland tissue extracts were subjected to western blot. Antibodies for VEGF, HIF-1a and HEXIM1 were used for immunoblotting. Anti-cytokeratin 18 was used as an epithelial cell marker and a loading control. Graph panel shows quantification of VEGF and HIF-1a expression from mice treated with or without doxycycline (DOX). Data represent mean±s.e.m. from four mice per group (±DOX) '*' and '**' indicate statistical significance (Po0.05 and Po0.005, respectively). (b) Western blot analyses of mammary gland extracts from adult wild-type mice (WT) and mice heterozygous for the HEXIM11-312 mutant allele (HEXIM1 het) using VEGF and HIF-1a antibodies. Blots were probed for cytokeratin 18 to normalize for epithelial cell content. Graph shows quantification of VEGF expression from WT and HEXIM11-312 heterozygous mice. Data represent mean ± s.e.m. from eight mice per group (VEGF) and at least three mice per group (HIF-1a); '*' indicates statistical significance (Po0.05). (c) Immunohistochemical detection of CD31 in mammary glands of lactating adult WT or HEXIM1 het mice. The panel is representative of four mice per group and graph shows quantification of %CD31-positive staining with mean±s.e.m.; '**' indicates statistical significance (Po0.005).
N Ogba et al Figure 5a, lanes 10-12) . However, HEXIM1 1À312 has a diminished capacity to inhibit ER-a transcriptional activity (Supplementary Figure  5b) . In the mammary glands of mice carrying the heterozygous allele for HEXIM1 1À312 (HEXIM1 het), we observed increases in VEGF and HIF-1a protein expression when compared with their wild-type littermates ( Figure 4b ). Taken together, these data suggest that the effects of the HEXIM1 insertional mutation on VEGF and HIF-1a protein expression are not due to a dysregulation of its P-TEFb-inhibitory function and that HEXIM1 modulates VEGF and HIF-1a expression in the mammary gland. As VEGF is a proangiogenic factor, we wanted to determine whether the enhanced expression of VEGF in the mammary glands of HEXIM1 het mice corresponded to increased vascularization in the mammary gland. A hallmark of angiogenesis is the presence of platelet endothelial cell adhesion molecule-1 or cluster of differentiation molecule 31 (CD31) on the cell surface of endothelial cells (Woodfin et al., 2007) . To carry out this, we examined any changes in CD31 expression in mammary glands from lactating HEXIM1 het mice and their wild-type lactating littermates using immunohistochemistry. We used mammary glands from lactating mice because increased vascularization and VEGF expression is critical for alveolar development and milk production (Rossiter et al., 2007) . We found that there was an increase in CD31-positive staining in the mammary glands of HEXIM1 het mice when compared with their wild-type littermates (Figure 4c ).
ER-a (Supplementary
In addition, in the mammary glands of mice homozygous for the HEXIM1 mutant allele (HEXIM1 1À312 ), we observed increased VEGF protein expression when compared with their wild-type littermates (Figure 5a ). There were no corresponding changes in cyclin D1 and the serine 2 phosphorylated form of RNAP II (Ser2 phosph RNAP II) protein levels (Figure 5a ), which have been used as markers of P-TEFb activity in vivo (Sims et al., 2004; Ogba et al., 2008) . To characterize the effect of enhanced VEGF expression in the mammary gland, we looked for any differences in epithelial cell proliferation in the mammary glands of HEXIM1 1À312 mice and their wild-type littermates and found that there was no significant difference in epithelial cell proliferation, as detected by bromodeoxyuridine incorporation (Supplementary Figure 6) . Taken together, the data indicate that HEXIM1 regulates VEGF and HIF-1a expression in mammary cells and this in turn regulates the development of blood vessels in the mammary gland. In addition, the regulation of VEGF by HEXIM1 in breast cells seems to have a P-TEFb-independent component.
HEXIM1 C-terminus mutation increases incidence of carcinogen-induced mammary tumorigenesis and correlates with increased tumor vascularization During tumorigenesis, hypoxic environments within the tumor enhance VEGF secretion and facilitate migration and proliferation of endothelial cells at the tumor site (Ferrara et al., 2003; Kimbro and Simons, 2006) . To HEXIM1 regulates VEGF function through ERa and HIF-1a N Ogba et al determine the effect of the HEXIM1 C-terminus mutant on tumorigenesis, we used a well-known experimental model of carcinogen-induced mammary tumors (Li et al., 1995) and treated HEXIM1 1À312 mice and their wild-type littermates with sub-threshold levels of the carcinogen 7,12-dimethylbenz(a)anthracene through oral gavage. Moreover, the HEXIM1 1À312 mice are in the C57/BL6 background strain that is known to be relatively resistant to carcinogen-induced tumors (Lydon et al., 1999) . We found that the HEXIM1 1À312 mice developed mammary tumors at a significantly higher incidence (Po0.001) than their wild-type littermates (Figure 5b) .
To determine whether enhanced vascularization of the mammary tumors may contribute to or is associated with the increase in tumor incidence in HEXIM1 1À312 mice, mammary tumors that developed were excised and processed for immunohistochemistry to detect any changes in vascularization. We found that tumors from HEXIM1 1À312 mice exhibited increased vascularization, as evidenced by an increase in CD31-positive staining, when compared with their wild-type littermates (Figure 5c ). Taken together, the in vivo data show that the HEXIM1 C-terminus mutation enhances mammary tumorigenesis and associated angiogenesis.
Discussion
This study demonstrates that HEXIM1 regulates VEGF expression in breast cancer cells through transcriptional regulation of ER-a and a regulation of HIF-1a expression under hypoxic conditions. We also demonstrate that HEXIM1 regulation of VEGF and HIF-1a occurs in the mouse mammary gland and leads to a modulation of mammary gland and tumor-associated angiogenesis. Taken together, these data support a novel role for HEXIM1 in mammary gland development and in mammary tumorigenesis partly through its effect on VEGF and angiogenesis.
Studies support the regulation of VEGF expression and angiogenesis in the female reproductive system and in breast cancer by estrogens, but specific mechanisms of the regulation are not always clear and E 2 has been shown to have variable effects on VEGF expression in breast cancer cells (Bogin and Degani, 2002; Garvin et al., 2005; Hyder, 2006) . Nonetheless, estrogenresponsive elements have been identified in the VEGF gene, and the recruitment of E 2 /ER-a to these regions has also been reported in breast, uterine and endometrial cancer cells (Stoner et al., 2004; Kazi et al., 2005; Molitoris et al., 2009) . It has also been reported that direct interaction between the tumor suppressor, BRCA1, and ER-a inhibits E 2 -driven VEGF transcription and secretion in breast cancer cells (Kawai et al., 2002) . In other studies, we have shown that HEXIM1 is an ER-a-interacting protein and tumor suppressor (Wittmann et al., 2003 (Wittmann et al., , 2005 . In this study, we found that increased HEXIM1 expression inhibited E 2 -induced VEGF transcription through inhibition of ER-a recruitment to the VEGF promoter in breast cancer cells. HEXIM1 also interacts with and inhibits the activity of the P-TEFb to regulate gene expression (Wittmann et al., 2005; Zhou and Yik, 2006; Ogba et al., 2008) . Other studies also support the P-TEFb-independent functions of HEXIM1 (Shimizu et al., 2005; Montano et al., 2008) . In this study, we found that both E 2 and HEXIM1 did not affect P-TEFb recruitment to the GC-rich/Sp1 region of the VEGF promoter. The data do not rule of a functional role for P-TEFb in E 2 /ER-a-regulated VEGF transcription, as our ChIP analyses was limited to examining the recruitment of P-TEFb to a specific E 2 -responsive region of the VEGF promoter. However, it does suggest that P-TEFb may not be involved in the regulation of VEGF by HEXIM1 at GC-rich/Sp1 region in the VEGF promoter.
Hypoxia, a strong inducer of VEGF expression, regulates VEGF transcription through HIF-1a binding to HRE in the VEGF promoter (Bos et al., 2004; Kimbro and Simons, 2006) . HIF-1a also has a role in tumor progression and metastasis (Liao et al., 2007) . As both estrogen and hypoxia are involved in tumor development and progression, it is thought that they enhance VEGF expression in concert (Maity et al., 2001; Seifeddine et al., 2007) . In this study, we found that HEXIM1 also inhibits VEGF transcription under hypoxic conditions through a decrease in E 2 -induced HIF-1a protein expression and a decrease in E 2 -induced HIF-1a recruitment to the HRE in the VEGF promoter. Previous studies have shown that E 2 -induced VEGF transcription in uterine cells is initiated rapidly through the phosphatidylinositol 3-kinase/Akt pathway with a concurrent integration of ER-a and HIF-1a signaling (Kazi et al., 2005 Kazi and Koos, 2007) . E 2 also induces increases in HIF-1a mRNA and protein expression in the uterus, which contributes to an increase in VEGF expression (Kazi et al., 2005 . However, in this study, E 2 induces increases in HIF-1a protein expression in ER-a expressing breast cancer cells without significantly affecting HIF-1a mRNA levels. In addition, increased HEXIM1 expression decreased E 2 -induced HIF-1a protein expression, without any effect on HIF-1a mRNA levels. Interestingly, the inhibition of E 2 -induced HIF-1a protein occurred only under low oxygen conditions. This suggests that HEXIM1 modulates E 2 -induced HIF-1a protein stability under hypoxia and warrants further study.
In addition, we demonstrate a physiological relevance for HEXIM1 regulation of VEGF expression in vivo. Increased HEXIM1 expression in the mammary gland of MMTV/HEXIM1 transgenic mice leads to a decrease in estrogen-driven VEGF and HIF-1a protein expression. Conversely, mutation of the C-terminus of HEXIM1 (HEXIM1 1À312 ) in mice led to enhanced VEGF and HIF-1a protein expression and vascularization in the mammary gland. In previous studies, we found that a deletion mutant form of HEXIM1 (HEXIM 1À310 ) was unable to inhibit E 2 /ER-a transcriptional activity (Wittmann et al., 2005) . In this study, we found that HEXIM 1À312 also has decreased the capacity to inhibit E 2 /ER-a transcriptional activity. This suggests HEXIM1 regulates VEGF function through ERa and HIF-1a N Ogba et al that the regulation of VEGF expression by HEXIM1 in the mouse mammary gland could be due to a dysregulation of ER-a, which would be consistent with our breast epithelial cell studies, and indicate that HEXIM1 inhibits the actions of ER-a and HIF-1a, two positive regulators of VEGF gene transcription. We deduced that this regulation is independent of P-TEFb, given that HEXIM1 1À312 was found to inhibit P-TEFb activity but did not seem to have an effect on the expression levels of cyclin D1 and serine 2 phosphorylated RNAP II in the mammary gland, which have been shown to be reflective of changes in P-TEFb activity in previous studies (Ogba et al., 2008) . However, we cannot completely rule out a role for P-TEFb in the regulation of VEGF transcription, as many genes contribute to VEGF transcriptional activity but are beyond the scope of our current study. VEGF also has an important role in endothelial cell migration and proliferation and the resulting angiogenesis contributes to physiological and pathological processes (Ellis and Hicklin, 2008) . We reported that a HEXIM1 C-terminus mutation leads to a decrease in VEGF expression in the developing mouse heart, which occurs through the attenuation of the inhibitory effect of C/EBPa by HEXIM1 on VEGF gene transcription in cardiomyocytes . In this study, we found that the HEXIM1 1À312 mice have increased susceptibility to developing carcinogen-induced mammary tumors that exhibit increased vascularization when compared with their wild-type littermates. The fact that HEXIM1 displays different effects on VEGF in cardiomyocytes compared with mammary epithelial cells suggests that there may be tissue-specific factors that associate with HEXIM1 to regulate VEGF expression. Nonetheless, taken together, our findings support a novel role for HEXIM1 during mammary gland development and tumorigenesis as illustrated in our model ( Figure 6 ).
VEGF-targeted therapy includes targeting circulating VEGF and VEGF receptor blockade (Ellis and Hicklin, 2008) . As cancer cells typically develop resistance to cancer therapeutic drugs, it is important to identify potential targets with multiple mechanisms of action. In breast cancer cells, HEXIM1 regulates proliferation (Wittmann et al., 2005; Ogba et al., 2008) and, as we show in this study, angiogenesis-two critical processes that occur during mammary tumorigenesis. Specifically, we found that HEXIM1 modulates E 2 -driven VEGF expression in breast cells through transcriptional regulation of ER-a and regulation of HIF-1a protein expression, with functional consequences on angiogenesis in the mammary gland and during carcinogeninduced mammary tumorigenesis. These studies elucidate the reasons why HEXIM1 might be a desirable therapeutic target for breast cancer. Future studies will aim to investigate the specific mechanisms of HEXIM1 regulation of HIF-1a expression and how it contributes to tumor progression.
Materials and methods
Reverse transcriptase-PCR analyses MCF-7 and MDA-MB-231 cells were obtained from American Type Culture Collection (Manassas, VA, USA) and maintained as previously described (Wittmann et al., 2003 (Wittmann et al., , 2005 . MCF-7 and MDA-MB-231 cells were transiently transfected with pCMV-Tag2B, pCMV-Tag2B-ER-a or pCMV-Tag2B-HEXIM1 using FuGENE HD transfection reagent (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. Cells were treated with E 2 and grown under high (21%) or low (1%) oxygen conditions as indicated. All cells were subsequently subjected to reverse transcriptase PCR analyses as previously described (Ogba et al., 2008) . PCR products were run in 2.5% agarose gels and visualized by ethidium bromide staining. A 12-bit digital camera captured fluorescence and signal intensities were quantified using the Alphaimager software from Alpha Innotech (San Leandro, CA, USA). Signals from genes of interest were normalized to signals from GAPDH and presented as 'relative mRNA expression.' The primers used and sequences are described in the Supplementary data.
Western analyses MCF-7 and MDA-MB-231 cells were treated as described and total protein was extracted from cells and used for western blot analysis as previously described (Ogba et al., 2008) .
ChIP assays MCF-7 and MDA-MB-231 cells were transfected as described with pCMV-Tag2B, pCMV-Tag2B-ER-a or pCMV-Tag2B-HEXIM1 using FuGENE HD transfection reagent (Roche). Cells were then treated with ethanol or 100 nM E 2 and grown under high (21%) or low (1%) oxygen conditions as indicated. ChIP assays were carried out as previously described (Ogba et al., 2008) . Signals from specific immunoprecipitations were normalized to signals from input DNA and presented as 'fold enrichment' relative to signals from untreated and untransfected sample groups set at '1'. The primers used and sequences are described in the Supplementary data.
CTD kinase assays
Kinase assays were carried out as previously described (Ogba et al., 2008) . See Supplementary data for complete description of assay.
Mice studies MMTV/HEXIM1 transgenic mice were generated and treated as previously described (Ogba et al., 2008) . HEXIM1 1À312 knock-in mutant mice were generated as previously described . Details of the studies carried out examining the effect of the HEXIM1 mutation on vascularization Figure 6 Model: HEXIM1 regulates VEGF expression through ER-a and HIF-1a to modulate angiogenesis and tumorigenesis.
HEXIM1 regulates VEGF function through ERa and HIF-1a N Ogba et al of the developing mammary gland and mammary tumors are described in the Supplementary data.
Immunohistochemistry
Immunohistochemistry using sections from mammary glands and tumors are described in the Supplementary data.
Data analyses
Data points in figures represent the means ± s.e.m. based on at least three independent experiments carried out in duplicate. The statistical significance was determined using Student's t test comparison for unpaired data and was indicated as follows: *Po0.05; **Po0.005; ***Po0.0005; ****Po0.00005.
